CELC logo

Celcuity Inc. (CELC)

$58.01

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CELC

Market cap

$2.85B

EPS

-4.71

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.165225

Price on CELC

Previous close

$60.57

Today's open

$60.60

Day's range

$56.64 - $60.97

52 week range

$53.54 - $151.02

Profile about CELC

CEO

Brian F. Sullivan

Employees

155

Headquarters

Minneapolis, MN

Exchange

NASDAQ Capital Market

Shares outstanding

49126314

Issue type

Common Stock

CELC industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CELC

Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review its supplemental New Drug Application (“sNDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. The FDA assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of June 25, 2027.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Celcuity Inc. (CELC) Q3 2026 Earnings Call Transcript

Celcuity Inc. ( CELC ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Jodi Sievers - Head of Investor Relations & Corporate Communications Brian Sullivan - Co-Founder, Chairman & CEO Vicky Hahne - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Tara Bancroft - TD Cowen, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Gil Blum - Needham & Company, LLC, Research Division Daniel Bronder - Cantor Fitzgerald & Co., Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Oliver McCammon - LifeSci Capital, LLC, Research Division Kalpit Patel - Wolfe Research, LLC Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Third Quarter 2026 Financial Results Call and Webcast. [Operator Instructions] This call is being recorded on Thursday, November 5, 2026.

news source

Seeking Alpha • Nov 8, 2026

news preview

What Celcuity (CELC) Said on Its Q3 Earnings Call

Celcuity NASDAQ: CELC reported a wider third-quarter loss as it prepared to commercialize its breast cancer treatment REVTORPYK, while executives said early orders and insurance coverage pointed to an encouraging launch.

news source

MarketBeat • Nov 6, 2026

news preview

Celcuity To Participate in Upcoming Investor Conferences

MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

news source

GlobeNewsWire • Nov 3, 2026

news preview

Celcuity: Stronger Clinical Evidence, Much Lower Valuation

Celcuity Inc. retains a Buy rating after REVTORPYK's FDA approval and robust mutant data, despite a significant share price drop. REVTORPYK demonstrated strong efficacy and safety, especially versus existing PI3K-targeted regimens, but faces competition from established oral drugs like Truqap. Management targets $2.5 billion peak sales, but base case models suggest substantial upside even at $1.2 billion with current US-only assumptions.

news source

Seeking Alpha • Oct 30, 2026

news preview

Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the third quarter 2026 after the market closes on Thursday, November 5, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update.

news source

GlobeNewsWire • Oct 29, 2026

news preview

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases

news source

GlobeNewsWire • Oct 24, 2026

news preview

Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026

Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone

news source

GlobeNewsWire • Oct 23, 2026

news preview

New Strong Sell Stocks for October 14th

ADDYY, CELC and CNL have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2026.

news source

Zacks Investment Research • Oct 14, 2026

news preview

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and other regimens evaluated in patients with HR+/HER2- advanced breast cancer Poster presentation of sub-group analyses from the Phase 1b trial of gedatolisib plus darolutamide in patients with mCRPC MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that a late breaking rapid oral presentation and three poster presentations will be featured at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2026 being held October 23-27, 2026, in Madrid, Spain. Data from its clinical trials of gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) locally advanced or metastatic breast cancer (“ABC”) and metastatic castration-resistant prostate cancer (“mCRPC”) will be presented.

news source

GlobeNewsWire • Oct 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Celcuity Inc.

Open an M1 investment account to buy and sell Celcuity Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CELC on M1